Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 40 patients (estimated)
- Sponsors
- Stanford University Cancer Institute (Palo Alto)
- Collaborators
- Orca Biosystems, Inc.
- Tags
- Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1643
- NCT Identifier
- NCT05088356
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.